B. J. Scallon, S. H. Tam, S. G. Mccarthy, A. N. Cai, and T. S. Raju, Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality, Mol. Immunol, vol.44, pp.1524-1558, 2007.

M. Dalziel, M. Crispin, C. N. Scanlan, N. Zitzmann, and R. A. Dwek, Emerging principles for the therapeutic exploitation of glycosylation, Science, vol.343, p.1235681, 2014.

R. B. Parekh, R. A. Dwek, B. J. Sutton, D. L. Fernandes, A. Leung et al., Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG, Nature, vol.316, pp.452-459, 1985.

F. Nimmerjahn and J. V. Ravetch, Divergent immunoglobulin ? subclass activity through selective Fc receptor binding, Science, vol.310, pp.1510-1512, 2005.

T. T. Wang, J. Sewatanon, M. J. Memoli, J. Wrammert, S. Bournazos et al., IgG antibodies to dengue enhanced for Fc?RIIIA binding determine disease severity, Science, vol.355, pp.395-403, 2017.

M. E. Ackerman, M. Crispin, X. Yu, K. Baruah, A. W. Boesch et al., Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity, J. Clin. Invest, vol.123, pp.2183-92, 2013.

Y. Kaneko, F. Nimmerjahn, and J. V. Ravetch, Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation, Science, vol.313, pp.670-673, 2006.

F. Nimmerjahn, Activating and inhibitory FcgammaRs in autoimmune disorders, Springer Semin. Immunopathol, vol.28, pp.305-324, 2006.

R. M. Anthony, F. Nimmerjahn, D. J. Ashline, V. N. Reinhold, J. C. Paulson et al., Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc, Science, vol.320, pp.373-379, 2008.

R. M. Anthony, F. Wermeling, M. Karlsson, and J. V. Ravetch, Identification of a receptor required for the anti-inflammatory activity of IVIG, Proc Natl Acad Sci, vol.105, pp.19571-19579, 2008.

I. Schwab, S. Mihai, M. Seeling, M. Kasperkiewicz, R. J. Ludwig et al., Broad requirement for terminal sialic acid residues and Fc?RIIB for the preventive and therapeutic activity of intravenous immunoglobulins in vivo, Eur J Immunol, vol.44, pp.1444-53, 2014.

N. Washburn, I. Schwab, D. Ortiz, N. Bhatnagar, J. C. Lansing et al., Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity, Proc Natl Acad Sci, vol.112, pp.1297-306, 2015.

P. Umaña, J. Jean-mairet, R. Moudry, H. Amstutz, and J. E. Bailey, Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibodydependent cellular cytotoxic activity, Nat. Biotechnol, vol.17, pp.176-80, 1999.

J. R. Gasdaska, S. Sherwood, J. T. Regan, and L. F. Dickey, An afucosylated anti-CD20 monoclonal antibody with greater antibody-dependent cellular cytotoxicity and B-cell depletion and lower complementdependent cytotoxicity than rituximab, Mol Immunol, vol.50, pp.134-175, 2012.

I. Quast, C. W. Keller, M. A. Maurer, J. P. Giddens, B. Tackenberg et al., Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity, J Clin Invest, vol.125, pp.4160-70, 2015.

I. Schwab, M. Biburger, G. Krönke, G. Schett, and F. Nimmerjahn, IVIg-mediated amelioration of ITP in mice is dependent on sialic acid and SIGNR1, Eur J Immunol, vol.42, pp.826-856, 2012.

R. B. Parekh, I. M. Roitt, D. A. Isenberg, R. A. Dwek, B. M. Ansell et al., Galactosylation of IgG associated oligosaccharides: reduction in patients with adult and juvenile onset rheumatoid arthritis and relation to disease activity, Lancet, vol.1, pp.966-975, 1988.

F. E. Van-de-geijn, M. Wuhrer, M. H. Selman, S. P. Willemsen, Y. A. De-man et al., Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study, Arthritis Res Ther, vol.11, 2009.

J. Novak, J. Barratt, B. A. Julian, and M. B. Renfrow, Aberrant glycosylation of the IgA1 molecule in IgA nephropathy, Semin Nephrol, vol.38, pp.461-76, 2018.

S. Hermouet, I. Corre, M. Gassin, E. Bigot-corbel, C. A. Sutton et al., Hepatitis C virus, human herpesvirus-8 and the development of plasma cell leukemia, New Engl J Med, vol.348, pp.178-187, 2003.

E. Bigot-corbel, M. Gassin, I. Corre, L. Carrer, D. Delaroche et al., Hepatitis C virus (HCV) infection, monoclonal immunoglobulin specific for HCV core protein, plasma-cell malignancy, Blood, vol.112, pp.4357-4365, 2008.

S. Nair, A. R. Branagan, J. Liu, C. S. Boddupalli, P. K. Mistry et al., Clonal immunoglobulin against lysolipids in the origin of myeloma, New Engl J Med, vol.374, pp.555-61, 2016.

A. Bosseboeuf, D. Feron, A. Tallet, C. Rossi, C. Charlier et al., Monoclonal IgG in MGUS and multiple myeloma target infectious pathogens

, J Clin Invest Insight, vol.5, p.95367, 2017.

S. Nair, J. Sng, S. Boddupalli, C. Seckinger, A. Chesi et al., Antigen-mediated regulation in monoclonal gammopathies and myeloma, J Clin Invest Insight, vol.3, p.98259, 2018.

K. D. Preuss, C. Hollak, N. Fadle, M. Van-oers, E. Regitz et al., Saposin C is a frequent target of paraproteins in Gaucher diseaseassociated MGUS/multiple myeloma, Br J Haematol, vol.184, pp.384-91, 2019.

A. Bosseboeuf, N. Mennesson, S. Allain-maillet, A. Tallet, E. Piver et al., Characteristics of MGUS and multiple myeloma according to the target of monoclonal immunoglobulins, glucosylsphingosine, or epstein-barr virus EBNA-1, Cancers, vol.12, p.1254, 2020.
URL : https://hal.archives-ouvertes.fr/inserm-02625782

A. Bosseboeuf, S. Allain, N. Mennesson, A. Tallet, C. Rossi et al., Proinflammatory state in MGUS and Myeloma is characterized by low sialylation of pathogen-specific and other monoclonal and polyclonal immunoglobulin G, Front. Immunol, vol.8, p.1347, 2017.

S. Nair, N. Bar, M. L. Xu, M. Dhodapkar, and P. K. Mistry, Glucosylsphingosine but not Saposin C, is the target antigen in Gaucher disease-associated gammopathy, Mol Genet Metab, vol.129, pp.286-91, 2020.

S. Panfilio, D. 'urso, P. Annechini, G. , D. 'elia et al., Regression of a case of Multiple Myeloma with antiviral treatment in a patient with chronic HCV infection, Leuk Res Rep, vol.2, pp.39-40, 2013.

R. García, A. Linares, M. Mennesson, N. Sanchez-vega, B. Sanchez et al., The role of Hepatitis C virus in the development of multiple myeloma: a case study, 60th Annual Meeting of the American Society of Hematology (ASH), vol.132, p.5592, 2018.

R. N. Damle, T. Wasil, F. Fais, F. Ghiotto, A. Valleto et al., Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia, Blood, vol.94, pp.1840-1847, 1999.

T. J. Hamblin, Z. Davis, A. Gardiner, D. G. Oscier, F. K. Stevenson et al., B-cell chronic lymphocytic leukemia, a clonal disease of B lymphocytes with receptors that vary in specificity for (auto)antigens, Ann N Y Acad Sci, vol.94, pp.1-2, 1999.

R. Catera, G. J. Silverman, K. Hatzi, T. Seiler, S. Didier et al., Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation, Mol Med, vol.14, pp.665-74, 2008.

L. Myhrinder, A. Hellqvist, E. Sidorova, E. Söderberg, A. Baxendale et al., A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies, Blood, vol.111, pp.3838-3886, 2008.

K. Hwang, A. M. Trama, and D. M. Kozink, IGHV1-69 B cell chronic lymphocytic leukemia antibodies cross-react with HIV-1 and hepatitis c virus antigens as well as intestinal commensal bacteria, PLoS ONE, vol.9, p.90725, 2014.